ExactAb™,低内毒素,已验证,无动物源,无叠氮钠,无载体,重组 级 提供 ≥95%(SDS-PAGE&SEC-HPLC) 纯度，适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存,避免反复冻融。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Girentuximab (anti-CA9)是一种嵌合单克隆抗体，可与碳酸酐酶IX (CAIX)结合，碳酸酐酶IX是一种在透明细胞肾细胞癌(ccRCC)中广泛表达的细胞表面糖蛋白。
Girentuximab (anti-CA9) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg
Girentuximab (anti-CA9) (Ab170927) - Flow Cytometry
Flow Cytometry analysis of HT-29 cells labelling CA9 (red) with Girentuximab (anti-CA9) (Ab170927). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Girentuximab (anti-CA9) (Ab170927) - Flow Cytometry
Flow Cytometry analysis of HeLa cells labelling CA9 (red) with Girentuximab (anti-CA9) (Ab170927). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Girentuximab (anti-CA9) (Ab170927) - SEC
The purity of Girentuximab (anti-CA9) (Ab170927) is more than 95% verified by HPLC.
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
 ZJ24F1011689 |
分析证书 | Ab170927 |
| ZJ24F1011690 |
分析证书 | Ab170927 |
| ZJ23F1001267 |
分析证书 | Ab170927 |
| ZJ23F1001268 |
分析证书 | Ab170927 |
我们的级别选择指南涵盖了目录中所有的变体的纯度、稳定剂状态和应用适用性。
查看 Animal Free 级别指南 → 查看 Carrier Free 级别指南 → 查看 Recombinant 级别指南 → 查看 Validated 级别指南 → 查看 ExactAb™ 级别指南 → 查看 Low Endotoxin 级别指南 → 查看 Azide Free 级别指南 →
危险品化学品经营许可证（带存储）